Amarin (AMRN) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Organon (OGN) has outperformed Amarin (AMRN) over the past year, gaining 30.1% versus a loss of 37.6%. Over five years, OGN leads with a -60.5% price change compared with -88.4% for AMRN. Organon is the larger company by market cap ($3.62 billion vs $253.9 million), about 14.3 times the size.
On valuation, Organon trades at a lower forward P/E (3.8x vs 12.3x for Amarin). Organon pays a dividend yielding 0.58%, while Amarin does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | OGN |
|---|---|---|
| Share price | $12.02 | $13.79 |
| Market cap | $253.90M | $3.62B |
| 1-day change | -0.41% | +0.36% |
| YTD return | -13.90% | +92.33% |
| 1-year return | -37.62% | +30.09% |
| 5-year return | -88.35% | -60.48% |
| P/E ratio (TTM) | — | 17.68 |
| Forward P/E | 12.27 | 3.81 |
| EPS (TTM) | $-1.20 | $0.78 |
| Dividend yield | 0.00% | 0.58% |
| Annual dividend | $0.00 | $0.08 |
| Revenue (latest FY) | — | $6.22B |
| Revenue growth (YoY) | — | -2.92% |
| Net income (latest FY) | — | $187.00M |
| Gross margin | — | 53.30% |
| Net margin | — | 3.01% |
| 52-week high | $20.90 | $13.79 |
| 52-week low | $11.83 | $5.69 |
| Distance from 52-week high | -42.49% | 0.00% |
| Analyst consensus | none | none |
| Avg. price target upside | +3.99% | -18.42% |
| Average volume | 66.03K | 2.65M |
| Shares outstanding | 21.12M | 262.61M |
| Employees | 80 | 10,000 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Organon is about 14.3 times larger than Amarin by market value ($3.62B vs $253.90M).
- OGN has outperformed AMRN by 67.7 percentage points over the past year.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Healthcare · Drug Manufacturers - General · 80 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Healthcare · Drug Manufacturers - General · 10,000 employees
AMRN vs OGN FAQ
Which is bigger, Amarin or Organon?
Organon (OGN) is larger, with a market capitalization of $3.62B compared with $253.90M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or OGN?
OGN returned +30.09% over the past 12 months, compared with -37.62% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Amarin or Organon?
Organon pays a dividend yielding 0.58%, while Amarin does not currently pay a regular dividend.
Are Amarin and Organon in the same industry?
Yes. Both are classified in the Drug Manufacturers - General industry within the Healthcare sector.